Von Hippel–Lindau (VHL) Insights and Trends

• VHL disease is a rare inherited multisystem disorder characterized by the development of cysts and highly vascular tumors in multiple organs, with a significant risk of malignant transformation. Its incidence is approximately 1 in 36,000 births, and the estimated de novo mutation rate is 4.4 × 10⁻⁶ per gamete per generation.
• Individuals with VHL disease have an increased risk of developing highly vascular tumors and cysts in multiple organs. Among the associated malignancies, renal cell carcinoma (kidney cancer) is the most common, affecting approximately 40% of patients with VHL.
• Most individuals with VHL disease inherit a pathogenic VHL gene mutation from an affected parent. However, approximately 20% of cases arise from a de novo (new) mutation, meaning the genetic alteration occurs spontaneously and is not inherited from either parent.

Von Hippel–Lindau (VHL) Epidemiology Forecast in the 7MM

• 2025 Total Prevalent Cases of Von Hippel–Lindau (VHL): ~XXXX million
• 2036 Projected Prevalent Cases of Von Hippel–Lindau (VHL): ~XXXX million
• Von Hippel–Lindau (VHL) Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Von Hippel–Lindau (VHL) Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the VHL, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

Von Hippel–Lindau (VHL) Understanding 

Von Hippel–Lindau (VHL) Overview

VHL disease is a rare, inherited autosomal dominant disorder caused by mutations in the VHL tumor suppressor gene, leading to the development of cysts and highly vascular tumors in multiple organs, including the kidneys, central nervous system, retina, pancreas, and adrenal glands. Dysregulation of the VHL–hypoxia-inducible factor (HIF) pathway promotes abnormal cell growth and angiogenesis, increasing the risk of both benign and malignant tumors. Renal cell carcinoma is the most common malignancy associated with VHL and a major cause of disease-related morbidity and mortality. 

Diagnosis of VHL is based on characteristic clinical manifestations, family history, and confirmation through genetic testing identifying a pathogenic VHL gene mutation. Regular surveillance using imaging studies, ophthalmologic examinations, and biochemical assessments is essential for early detection of VHL-associated tumors. Timely diagnosis and continuous monitoring are critical to enabling early intervention, reducing complications, and improving long-term patient outcomes.

Note: Further details are provided in the report.

Von Hippel–Lindau (VHL) Epidemiology

Key Findings from VHL Epidemiological Analysis and Forecast 

• As per the National Cancer Institute (2021), the prevalence of VHL is estimated to be between 1 in 31,000 and 1 in 91,000 individuals.
• According to Cancer.Net (2020), it is estimated that about 1 in 30,000 people have VHL. About 10% of people with VHL do not have any family history of the condition. They have a de novo mutation, meaning a new mutation in the VHL gene not present in their parents.
• According to the National Institute for Health Research Innovation Observatory (NIHRIO) (2021), in the UK, RCCs are found in 24% to 45% of patients with VHL and are the primary inherited renal cancer. The mean age of RCC onset in VHL patients is 39 years old.
• According to the National Organization of Rare Disorders (NORD), VHL disease affects 1 in 36,000 people (10,000 cases in the United States and 200,000 cases worldwide), and 20% of patients are first-in-family or de novo cases. 
• The mean age of onset is 26 years, and 97% of people with a VHL gene mutation have symptoms by the age of 65. 
• VHL disease affects males and females and all ethnic groups equally, and occurs in all parts of the world.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of VHL, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Von Hippel–Lindau (VHL) Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of VHL? What will be the growth opportunities across the 7MM concerning the patient population with VHL?
• What is the historical and forecasted VHL patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.